Literature DB >> 27886692

Cardiovascular Disease Risk in Patients with Rheumatic Diseases.

Rachel H Mackey1, Lewis H Kuller2, Larry W Moreland3.   

Abstract

Evidence suggests the greater than 1.5 increased risk of cardiovascular disease (CVD) in rheumatoid arthritis (RA) is related to an accelerated burden of subclinical atherosclerosis that develops before the diagnosis of RA. Dyslipidemia in RA is better quantified by lipoproteins and apolipoproteins than cholesterol levels. Current risk factors likely underestimate CVD risk partly by underestimating prior risk factor levels. To reduce CVD risk in RA, control disease activity and aggressively treat CVD risk factors. Some of the two-fold higher risk of heart failure and total mortality in RA may be due to myocardial disease caused by inflammation. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cardiovascular; Lipids; Lipoproteins; Myocardial fibrosis; Rheumatoid arthritis

Mesh:

Year:  2017        PMID: 27886692     DOI: 10.1016/j.cger.2016.08.008

Source DB:  PubMed          Journal:  Clin Geriatr Med        ISSN: 0749-0690            Impact factor:   3.076


  9 in total

Review 1.  Managing Cardiovascular Disease Risk in Rheumatoid Arthritis: Clinical Updates and Three Strategic Approaches.

Authors:  Ann M Chodara; Aimée Wattiaux; Christie M Bartels
Journal:  Curr Rheumatol Rep       Date:  2017-04       Impact factor: 4.592

2.  Risk of adverse outcomes in patients with rheumatoid arthritis hospitalized for stroke-a cross-sectional study.

Authors:  Jiunn-Horng Kang; Sudha Xirasagar; Herng-Ching Lin; Pai-Feng Kao; Li-Chin Sung
Journal:  Clin Rheumatol       Date:  2018-09-12       Impact factor: 2.980

3.  Concordance between the Different Cardiovascular Risk Scores in People with Rheumatoid Arthritis and Psoriasis Arthritis.

Authors:  Cristina Gonzalez-Martin; Silvia Grande Morais; Sonia Pertega-Diaz; Teresa Seoane-Pillado; Vanesa Balboa-Barreiro; Raquel Veiga-Seijo
Journal:  Cardiol Res Pract       Date:  2019-03-14       Impact factor: 1.866

4.  Levels of Lipoprotein (a) in patients with coronary artery disease with and without inflammatory rheumatic disease: a cross-sectional study.

Authors:  Sverre Holm; Ingvild Oma; Tor-Arne Hagve; Kjell Saatvedt; Frank Brosstad; Knut Mikkelsen; Hans Rydningen; Ivar Risnes; Sven Martin Almdahl; Thor Ueland; Pål Aukrust; Bente Halvorsen; Ivana Hollan
Journal:  BMJ Open       Date:  2019-05-10       Impact factor: 2.692

5.  Usefulness of resveratrol supplementation in decreasing cardiometabolic risk factors comparing subjects with metabolic syndrome and healthy subjects with or without obesity: meta-analysis using multinational, randomised, controlled trials.

Authors:  Consolato Sergi; Bonnie Chiu; Joseph Feulefack; Fan Shen; Brian Chiu
Journal:  Arch Med Sci Atheroscler Dis       Date:  2020-05-30

6.  Role of Folic Acid Drugs in the Treatment with Antithrombotic and Anticoagulant Drugs for Patients with Cardiovascular Diseases Based on the Analysis of Virtual Reality Medical Data.

Authors:  Aiguo Zhang; Jing Wang; Qiang Jing
Journal:  J Healthc Eng       Date:  2021-08-04       Impact factor: 2.682

7.  Characteristics of Ang-(1-7)/Mas-Mediated Amelioration of Joint Inflammation and Cardiac Complications in Mice With Collagen-Induced Arthritis.

Authors:  Zhongjie Wang; Wenhan Huang; Feifeng Ren; Lei Luo; Jun Zhou; Dongmei Huang; Mei Jiang; Huaan Du; Jinqi Fan; Lin Tang
Journal:  Front Immunol       Date:  2021-05-17       Impact factor: 7.561

8.  Adenovirus-mediated delivery of Sema3A alleviates rheumatoid arthritis in a serum-transfer induced mouse model.

Authors:  Yue Teng; Zhanhai Yin; Jing Li; Kun Li; Xu Li; Yan Zhang
Journal:  Oncotarget       Date:  2017-08-03

9.  Reducing Low-Density Lipoprotein Cholesterol After Myocardial Infarction in Older Individuals, Levels Versus Change: Can Observational Studies Answer the Questions?

Authors:  Lewis H Kuller
Journal:  J Am Heart Assoc       Date:  2018-05-12       Impact factor: 5.501

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.